What if I told you that eating sugar cookies and cherry pie could help slow down the progression of ALS symptoms? You’d probably say, “Hey Dagmar, you’ve gone bananas!” I know, I know. The suggestion sounds contrary to what we’ve always been told about healthy eating, especially for anyone…
Sorting out the sometimes confusing advice on ALS and diet
People with amyotrophic lateral sclerosis (ALS) given PrimeC in the PARADIGM Phase 2b trial — and who did not diverge in major ways from the trial’s rules — experienced a significant slowing in disease progression compared with a placebo, the treatment’s developer, NeuroSense Therapeutics, announced. This finding…
Treatment with Relyvrio (sodium phenylbutyrate and taurursodiol) significantly reduced blood levels of neuroinflammatory biomarkers in people with amyotrophic lateral sclerosis (ALS) as early as three months, according to a post hoc analysis of the CENTAUR trial. Data from the Phase 2 study (NCT03127514) demonstrated that reductions in…
BrainStorm Cell Therapeutics has had a meeting with the U.S. Food and Drug Administration (FDA) seeking an agreement on its plans for a confirmatory Phase 3b trial of NurOwn, a cell-based treatment the company is developing for amyotrophic lateral sclerosis (ALS). The main goal of the meeting,…
A few weeks before Christmas Day in 2018, my late husband, Jeff, and I sat side by side on the edge of our bed, preparing to create the most meaningful Christmas gifts we’d ever given. Laid out beside us on the bed were four children’s storybooks, each with a Christmas…
“The essence of trauma is powerlessness.” This quote from Christian trauma therapist Colleen Ramser grabbed my attention, because I often feel powerless as a caregiver for my husband, Todd, who is paralyzed by ALS. We’ve been having a rough week. Todd’s shower aide called in sick a…
Under a new agreement, Coya Therapeutics’ amyotrophic lateral sclerosis (ALS) treatment candidate COYA 302 — which aims to suppress chronic and sustained inflammation — will now be exclusively marketed by Dr. Reddy’s Laboratories in the U.S., Canada, and the U.K., as well as in the European Union, should…
The ALS Association has given Oryzon Genomics nearly $500,000 to advance ORY-4001, a potential treatment of amyotrophic lateral sclerosis (ALS), into preclinical studies. The $498,690 grant was provided via the association’s Lawrence and Isabel Barnett Drug Development Program. Oryzon intends for laboratory studies in mouse disease models…
One important habit I enjoy doing every day is keeping up with the latest ALS-related news and research. But every once in a while, I come across an article that has me muttering, “Was this research even needed?” And more often than not, I answer my own question with, “Well,…
NeuroSense Therapeutics’ PrimeC was found to be safe and well tolerated in a Phase 2b trial, and use of the oral therapy for six months led to “meaningful slowing of disease progression” in people with amyotrophic lateral sclerosis (ALS), the company said in a press release announcing top-line…
Recent Posts
- Learning ALS self-advocacy involves being a little pushy
- Brain implant decodes finger moves so paralyzed patients can type
- Grant funds new ALS treatment approach targeting TDP-43 pathway
- Amydis awarded $2.5M to develop diagnostic eye test for ALS
- Mourning the loss of a leader, friend, and advocate for women with ALS